drugset / Trial / NCT06871007
Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
Addition of nivolumab (immune checkpoint inhibitor) to standard chemotherapy (DA-EPOCH-R) may improve outcome in children with primary mediastinal large B-cell lymphoma
Timeline
- Start
- 2024-09-01
- Primary completion
- 2029-09-01
- Completion
- 2031-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 40 mg | — |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 10 mg/m2 | — |
| Background | Etoposide | Small molecule | 50 mg/m2 | — |
| Background | Prednisolone | Other / unclassified | 60 mg/m2 | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Background | Vincristine | Small molecule | 0.4 mg/m2 | — |